About Us

experience excellence

We’re a Biotech R&D Company.

Over 1.5 billion people worldwide suffer from hearing disorders, including hearing loss due to aging (Age-related Hearing Loss, ARHL) or noise exposure (Noise-Induced Hearing Loss, NIHL). In the U.S. alone, hearing disorders affect 73 million Americans. The National Institute for Occupational Safety and Health estimates that each year over 22 million workers are exposed to damaging levels of noise and hearing loss is the most common work-related illness in the U.S. Currently, there are no drugs approved by the US Food and Drug Administration (FDA) on the market for hearing loss prevention or treatment of hearing loss.

With a decade of product development funded by initial investment from co-founders and subsequent awards from National Institutes of Health (NIH), Gateway Biotechnology has been developing drug candidates with proven safety records to combat hearing disorders. Our innovative approach, grounded in a deep understanding of basic mechanisms underlying hearing loss, targets multiple cellular pathways with new product formulations that fine-tune drug delivery to the ear.

Talented professionals

Combined Experience

Jianxin Bao, Ph.D.
CEO/Founder

Dr. Bao started his independent research career in auditory neuroscience at Columbia University and later became a tenured faculty at Washington University in St. Louis. With over 20 years of research experience in the field of hearing disorders, Dr. Bao’s research excellence has been recognized by multiple awards from National Institute on Aging and the National Institute on Deafness and Other Communication Disorders. His interactions with clinicians and researchers at both academic and industrial institutions led to the formation of Gateway Biotechnology Inc., which focuses on developing new products for hearing disorders.
Richard Chole, M.D., Ph.D
Co-founder

Dr. Chole is a well-known clinician with a specialty in neurotology, and he has also led multiple funded research projects in the Department of Otolaryngology at Washington University in St. Louis. Dr. Chole carried out the first study of age-related hearing loss in the C57BL/6J strain of mice. He has experience in clinical studies and has conducted several randomized clinical trials in the field of hearing disorders. Dr. Chole's clinical interests include otology, neurotology, reconstruction of the middle ear, petrous apicitis, otosclerosis, cholesteatoma, Meniere's disease, cochlear implants and bone-anchored hearing aids.
Philip Perez, M.D.
CMO/Co-founder Philip Perez, M.D.

Dr. Perez received his undergraduate education at Harvard University and his medical school education at Washington University in St. Louis. He has been involved in the first drug repurposing studies against hearing loss at Washington University in St. Louis. He is now practicing at the Department of Otolaryngology-Head and Neck Surgery at the University of California in San Francisco.
Nick Akers
President at Gateway Biotechnology Inc.
Dr. Thomas Brutnell, PhD, VP R&D
30+ Yrs R&D experience in academia and industry; Co-founder, former CSO Benson Hill, 30+ million raise through Series B
Dr. John Hawks, PhD, CSO
Former Professor at Kent State Univ, 40+ yrs clinical audiology and business development expertise
Dr. Richard Tyler, PhD
President at Gateway Biotechnology Inc.
Dr. Kevin Ohlemiller, PhD
Associate Professor of Otolaryngology WUSTL Developed animal model systems for Age-Related Hearing Loss, Noise-Induced Hearing Loss
Dr. Richard Tyler, PhD
Professor of Otolaryngology University of Iowa World-expert in tinnitus research; developed Tinnitus Activities Treatment therapy
Jianxin Bao, Ph.D.
CEO/Founder

Dr. Bao started his independent research career in auditory neuroscience at Columbia University and later became a tenured faculty at Washington University in St. Louis. With over 20 years of research experience in the field of hearing disorders, Dr. Bao’s research excellence has been recognized by multiple awards from National Institute on Aging and the National Institute on Deafness and Other Communication Disorders. His interactions with clinicians and researchers at both academic and industrial institutions led to the formation of Gateway Biotechnology Inc., which focuses on developing new products for hearing disorders.
Richard Chole, M.D., Ph.D
Co-founder

Dr. Chole is a well-known clinician with a specialty in neurotology, and he has also led multiple funded research projects in the Department of Otolaryngology at Washington University in St. Louis. Dr. Chole carried out the first study of age-related hearing loss in the C57BL/6J strain of mice. He has experience in clinical studies and has conducted several randomized clinical trials in the field of hearing disorders. Dr. Chole's clinical interests include otology, neurotology, reconstruction of the middle ear, petrous apicitis, otosclerosis, cholesteatoma, Meniere's disease, cochlear implants and bone-anchored hearing aids.
Philip Perez, M.D.
CMO/Co-founder Philip Perez, M.D.

Dr. Perez received his undergraduate education at Harvard University and his medical school education at Washington University in St. Louis. He has been involved in the first drug repurposing studies against hearing loss at Washington University in St. Louis. He is now practicing at the Department of Otolaryngology-Head and Neck Surgery at the University of California in San Francisco.
Nick Akers
President at Gateway Biotechnology Inc.
Dr. Thomas Brutnell, PhD, VP R&D
30+ Yrs R&D experience in academia and industry; Co-founder, former CSO Benson Hill, 30+ million raise through Series B
Dr. John Hawks, PhD, CSO
Former Professor at Kent State Univ, 40+ yrs clinical audiology and business development expertise
Dr. Richard Tyler, PhD
President at Gateway Biotechnology Inc.
Dr. Kevin Ohlemiller, PhD
Associate Professor of Otolaryngology WUSTL Developed animal model systems for Age-Related Hearing Loss, Noise-Induced Hearing Loss
Talented professionals

Combined Experience

Jianxin Bao, Ph.D.
CEO/Founder
Richard Chole, M.D., Ph.D
Co-founder
Philip Perez, M.D.
CMO/Co-founder Philip Perez, M.D.
Nick Akers
President at Gateway Biotechnology Inc.
Dr. Thomas Brutnell, PhD, VP R&D
30+ Yrs R&D experience in academia and industry; Co-founder, former CSO Benson Hill, 30+ million raise through Series B
Dr. John Hawks, PhD, CSO
Former Professor at Kent State Univ, 40+ yrs clinical audiology and business development expertise
Dr. Richard Tyler, PhD
President at Gateway Biotechnology Inc.
Dr. Kevin Ohlemiller, PhD
Associate Professor of Otolaryngology WUSTL Developed animal model systems for Age-Related Hearing Loss, Noise-Induced Hearing Loss
Dr. Richard Tyler, PhD
Professor of Otolaryngology University of Iowa World-expert in tinnitus research; developed Tinnitus Activities Treatment therapy